FDA approves second-ever treatment for Alzheimer's agitation

Overview

Until May 2023, no drug was approved in the United States to treat the agitation that affects up to three-quarters of people with Alzheimer's disease. Doctors reached for antipsychotics off-label, a class of medicines that carries a black-box warning for increased death risk in older dementia patients. On April 30, 2026, the FDA approved Axsome Therapeutics' Auvelity for the indication, doubling approved options from one to two. The FDA called it the 'first non-antipsychotic drug to treat agitation associated with dementia' — what sets it apart from Rexulti.

Auvelity is an oral pill combining dextromethorphan, the cough-suppressant ingredient, with bupropion, an older antidepressant that slows dextromethorphan's breakdown so it can act on the brain. In two pivotal trials, patients on Auvelity relapsed into agitation at 8.4 percent versus 28.6 percent on placebo. Axsome had doubled its salesforce to 600 in the months before approval and activated its Auvelity OnMySide patient support program on approval day, offering savings cards and prior authorization assistance for commercially insured patients. AXSM shares surged, and the company is scheduled to report Q1 2026 financial results on May 4 — its first quarterly disclosure following the new indication.

Why it matters

If a parent develops Alzheimer's agitation, the doctor now has two approved treatments to try—up from zero in 2022.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

2nd

FDA-approved treatment for Alzheimer's agitation

Joins brexpiprazole (Rexulti), approved in May 2023 as the first ever.

~76%

of Alzheimer's patients experience agitation

Symptoms range from restlessness and pacing to aggression and shouting.

8.4% vs 28.6%

relapse rate on Auvelity vs placebo

ACCORD-2 randomized withdrawal trial measured time to agitation relapse.

~7M

Americans living with Alzheimer's

Population that defines the addressable patient pool for the new indication.

approved treatments before May 2023

Off-label antipsychotics carried a black-box warning for increased death risk.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Timeline Five events from this story — drag them oldest to newest. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Herriot Tabuteau

Leading commercial launch of second Auvelity indication

George Grossberg

Provided clinical endorsement at Auvelity approval

Organizations Involved

Axsome Therapeutics

Biopharmaceutical company

Commercial launch underway; 600-rep salesforce and OnMySide patient support program activated on day of approval

A New York-based biotech focused on central nervous system disorders, built around reformulating known compounds for new indications.

U.S. Food and Drug Administration

Federal Agency

Issued approval on PDUFA action date

The federal agency that reviews and approves prescription drugs in the United States.

Otsuka & Lundbeck

Pharmaceutical co-developers

Maker of incumbent treatment Rexulti

The pharmaceutical partners that brought brexpiprazole (Rexulti)—the first FDA-approved Alzheimer's agitation treatment—to market in 2023.

Timeline

April 2005 May 2026

9 events Latest: May 4th, 2026 · 1 month ago

Tap a bar to jump to that date

May 2026
Q1 2026 earnings call scheduled
Latest Corporate

Axsome is set to report first-quarter 2026 financial results before U.S. markets open — the first quarterly report to include management commentary on Alzheimer's agitation launch momentum.
May 4th, 2026 • 8:00 AM
Axsome holds post-approval investor webcast
Corporate

Axsome hosted a conference call at 8:00 a.m. ET to discuss the FDA approval, immediate commercial launch infrastructure, and the Auvelity OnMySide patient support program.
May 1st, 2026 • 8:00 AM
April 2026
FDA approves Auvelity for Alzheimer's agitation
Approval

On the assigned action date, the FDA clears Auvelity as the second-ever approved treatment for agitation associated with dementia due to Alzheimer's disease.
April 30th, 2026
June 2025
Axsome submits supplemental New Drug Application
Regulatory

Company files for the Alzheimer's agitation indication; FDA accepts the submission and assigns a 2026 action date.
June 2025
August 2024
ACCORD-2 relapse-prevention trial reports
Clinical Trial

Patients stabilized on Auvelity relapsed at 8.4 percent versus 28.6 percent on placebo, providing the relapse-prevention evidence the FDA reviewed.
August 2024
January 2024
ADVANCE-1 Phase 3 results published
Clinical Trial

Axsome reports that Auvelity significantly reduced agitation versus placebo in patients with Alzheimer's, supporting the regulatory filing.
January 29th, 2024
May 2023
Rexulti becomes first-ever Alzheimer's agitation treatment
Approval

FDA approves brexpiprazole for agitation associated with dementia due to Alzheimer's disease, ending decades without an approved option.
May 10th, 2023
August 2022
Auvelity wins first FDA approval, for depression
Approval

FDA clears Axsome's dextromethorphan-bupropion combination for major depressive disorder, establishing the safety and pharmacology base for later indications.
August 18th, 2022
April 2005
FDA black-box warning shapes off-label landscape
Regulatory

The FDA warns that atypical antipsychotics increase mortality in elderly dementia patients, leaving clinicians with no approved option and a dangerous off-label one.
April 11th, 2005

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 2023

Rexulti approved as first Alzheimer's agitation treatment (2023)

After more than a decade of failed trials by multiple sponsors, the FDA approved Otsuka and Lundbeck's brexpiprazole for agitation in dementia due to Alzheimer's disease. Two pivotal trials showed modest but statistically significant reductions in agitation scores versus placebo.

Then

The approval established the first FDA-cleared option in a category where doctors had relied on off-label antipsychotics carrying mortality warnings.

Now

It validated the regulatory pathway for dementia-symptom drugs and incentivized other sponsors—including Axsome—to push their own programs to filing.

Why this matters now

Rexulti's approval created the category that Auvelity now expands. Without that 2023 precedent, the regulatory and reimbursement frameworks Auvelity steps into would not exist.

April 2005

FDA black-box warning on antipsychotics for dementia (2005)

The FDA required a black-box warning on atypical antipsychotics—including risperidone, olanzapine, and quetiapine—after pooled trial data showed elderly patients with dementia-related psychosis faced roughly 1.6 to 1.7 times the mortality risk of those on placebo. The warning was extended to all antipsychotics in 2008.

Then

Off-label prescribing dropped initially but rebounded because clinicians had no approved alternatives for severe agitation.

Now

The warning created a durable regulatory and ethical incentive to develop dementia-specific drugs without antipsychotic mechanisms—the gap Auvelity now partially fills.

Why this matters now

Auvelity's value is defined by what it is not: an antipsychotic. The black-box warning is the policy backdrop that makes a non-antipsychotic mechanism commercially and clinically meaningful.

June 2021 to early 2024

Aduhelm conditional approval and rollback (2021–2024)

The FDA granted accelerated approval to Biogen's Aduhelm for Alzheimer's disease over the objections of its own advisory committee, citing reductions in amyloid plaques rather than clear cognitive benefit. Medicare restricted coverage, sales collapsed, and Biogen discontinued the drug in early 2024.

Then

The approval triggered congressional investigations and damaged trust in the FDA's accelerated approval pathway.

Now

Subsequent Alzheimer's-related approvals have faced sharper scrutiny on trial design and clinical meaningfulness, raising the evidentiary bar that Auvelity's program had to clear.

Why this matters now

Auvelity entered FDA review in the post-Aduhelm environment, where dementia drug approvals attract heightened scrutiny. Its replicated, placebo-controlled trial package reflects what the agency now requires to act in this space.